C型肝炎：治療情勢に革命をもたらすための形勢を一変させる体制 - KOLの洞察
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
|出版日||ページ情報||英文 163 pages
|C型肝炎：治療情勢に革命をもたらすための形勢を一変させる体制 - KOLの洞察 Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight|
|出版日: 2014年04月01日||ページ情報: 英文 163 pages||
The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the protease inhibitors and interferon regimens. With convenient, efficacious and safer therapies coming through the pipeline-led by Gilead, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim-the battle to transform this potentially lucrative market will be intense.
Therapy Trends: Hepatitis C is compiled from exclusive, in-depth interviews with the world's leading KOLs in HCV. It identifies and analyses the major factors, advances and trends currently influencing the HCV treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future HCV management.
FirstWord selected KOLs for this report based on their level of engagement and influence within the HCV pharmaceutical industry, and on their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how HCV clinical research will shape the future market.
Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent insights gained from the field's key opinion leaders. The results of FirstWord's research and analysis will help you to:
The hepatitis C (HCV) market is expected to become one of the fastest growing markets in Pharma over the next decade given a sizable 170 million patient population, a significant unmet need and rapid advancements in the clinic. The management of this infectious disease is on the edge of a revolution that will bring considerable changes to the treatment algorithm. KOLs from North America and Europe provide answers to some critical questions regarding the global HCV market, including:
list> What do KOLs make of the Sovaldi and Olysio and their impact on treatment? What are the current unmet needs and major challenges in HCV treatment? What are the most promising late-stage classes in development? Which therapies are KOLs eagerly awaiting? How will the nucleotide inhibitors, non-nucs, and NS5A inhibitors be positioned in the HCV market? How do the second generation protease inhibitors differ from their first-generation cousins? In what ways could eventual biomarkers improve future HCV disease management? How will treatment of HCV look in the future? How do KOLs think the pricing environment will shape the uptake of new HCV treatments? What clinical research trends do KOLs predict for future HCV therapies?